In This Article:
As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.
Top 10 Undervalued Stocks Based On Cash Flows
Name | Current Price | Fair Value (Est) | Discount (Est) |
Türkiye Sise Ve Cam Fabrikalari (IBSE:SISE) | TRY41.22 | TRY82.15 | 49.8% |
PharmaResearch (KOSDAQ:A214450) | ₩213500.00 | ₩426006.27 | 49.9% |
Giant Biogene Holding (SEHK:2367) | HK$48.30 | HK$96.27 | 49.8% |
DAEDUCK ELECTRONICS (KOSE:A353200) | ₩14050.00 | ₩28039.12 | 49.9% |
Power Root Berhad (KLSE:PWROOT) | MYR1.46 | MYR2.92 | 50% |
Enento Group Oyj (HLSE:ENENTO) | €18.02 | €35.91 | 49.8% |
EuroGroup Laminations (BIT:EGLA) | €2.726 | €5.42 | 49.7% |
Fine Foods & Pharmaceuticals N.T.M (BIT:FF) | €7.84 | €15.60 | 49.7% |
First Advantage (NasdaqGS:FA) | US$19.37 | US$38.63 | 49.9% |
AeroVironment (NasdaqGS:AVAV) | US$203.19 | US$404.34 | 49.7% |
We'll examine a selection from our screener results.
argenx
Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China, with a market cap of €35.60 billion.
Operations: The company's revenue segment is biotechnology, generating $1.91 billion.
Estimated Discount To Fair Value: 35%
argenx is trading at 35% below its estimated fair value, with a projected revenue growth of 25% per year, outpacing the Belgian market. Recent earnings show significant improvement, with US$588.88 million in Q3 revenue and US$91.41 million net income. The company continues to advance its efgartigimod SC development following positive Phase 2 results in myositis treatment studies, potentially enhancing future cash flows and supporting its undervaluation thesis based on discounted cash flow analysis.
-
The growth report we've compiled suggests that argenx's future prospects could be on the up.
-
Click to explore a detailed breakdown of our findings in argenx's balance sheet health report.
Sweco
Overview: Sweco AB (publ) offers architecture and engineering consultancy services globally, with a market cap of SEK60.04 billion.
Operations: The company's revenue segments are distributed as follows: Sweco UK with SEK1.48 billion, Sweco Norway at SEK3.48 billion, Sweco Sweden contributing SEK8.88 billion, Sweco Belgium at SEK3.99 billion, Sweco Denmark with SEK3.38 billion, Sweco Finland generating SEK3.62 billion, Sweco Netherlands at SEK3.28 billion, and Sweco Germany & Central Europe providing SEK2.78 billion in revenue.